All In Biotech

Drug Trial Radar · NCT06846320

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

315

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Generalized Anxiety Disorder (GAD)

Interventions

  • ABBV-932Drug

    Oral Capsule

  • Placebo for ABBV-932Drug

    Oral Capsule

  • Antidepressant Therapy (ADT)Drug

    Standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 10 weeks
  2. Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total ScoreTime frame: Up to approximately 6 weeks

Locations

52 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama - Huntsville Regional Medical Campus /ID# 267818

    Huntsville, Alabama · Recruiting

  • Ima Clinical Research Phoenix (Alea) /ID# 275737

    Phoenix, Arizona · Recruiting

  • Noble Clinical Research /ID# 267952

    Tucson, Arizona · Completed

  • Advanced Research Center /ID# 267874

    Anaheim, California · Recruiting

  • Axiom Research /ID# 267814

    Colton, California · Recruiting

  • Sun Valley Research Center /ID# 267864

    Imperial, California · Recruiting

  • Synergy San Diego /ID# 267879

    Lemon Grove, California · Recruiting

  • Alliance for Research Alliance for Wellness /ID# 267911

    Long Beach, California · Recruiting

  • NRC Research Institute DTLA /ID# 267832

    Los Angeles, California · Recruiting

  • Excell Research /ID# 267918

    Oceanside, California · Recruiting

  • Inland Psychiatric Medical Group /ID# 268598

    Temecula, California · Recruiting

  • Sunwise Clinical Research /ID# 267863

    Walnut Creek, California · Recruiting

  • Connecticut Clinical Research - Cromwell /ID# 271241

    Cromwell, Connecticut · Recruiting

  • Cns Healthcare - Jacksonville /ID# 268588

    Jacksonville, Florida · Recruiting

  • Accel Research Sites Network - St. Pete /ID# 267821

    Largo, Florida · Recruiting

  • K2 Medical Research, LLC /ID# 267841

    Maitland, Florida · Recruiting

  • GMI Florida - Central Miami Medical Institute /ID# 267839

    Miami, Florida · Recruiting

  • Allied Biomedical Res Inst Inc /ID# 267813

    Miami, Florida · Recruiting

  • Apg Research /ID# 271707

    Orlando, Florida · Recruiting

  • Psych Atlanta /ID# 267878

    Marietta, Georgia · Recruiting

  • iResearch Savannah /ID# 267865

    Savannah, Georgia · Recruiting

  • University of Chicago Medical Center /ID# 275131

    Chicago, Illinois · Recruiting

  • Collective Medical Research /ID# 272015

    Overland Park, Kansas · Recruiting

  • CenExel /ID# 267853

    Gaithersburg, Maryland · Recruiting

  • Elixia - Springfield /ID# 267815

    Springfield, Massachusetts · Recruiting

  • Psychiatric Care And Research Center /ID# 271701

    O'Fallon, Missouri · Recruiting

  • Saint Charles Psychiatric Associates /ID# 271202

    Saint Charles, Missouri · Recruiting

  • Arch Clinical Trials /ID# 267851

    St Louis, Missouri · Recruiting

  • Ima Clinical Research Las Vegas (SMO/Network/Consortium) /ID# 275731

    Las Vegas, Nevada · Recruiting

  • Duplicate_Oasis Clinical Research, LLC /ID# 267953

    Las Vegas, Nevada · Completed

  • Princeton Medical Institute /ID# 267877

    Princeton, New Jersey · Recruiting

  • Bio Behavioral Health /ID# 267919

    Toms River, New Jersey · Recruiting

  • Integrative Clinical Trials /ID# 279519

    Brooklyn, New York · Recruiting

  • New Hope Clinical Research - Inpatient unit /ID# 267810

    Charlotte, North Carolina · Recruiting

  • Quest Therapeutics of Avon /ID# 267829

    Avon Lake, Ohio · Recruiting

  • University Of Cincinnati Medical Center /ID# 271704

    Cincinnati, Ohio · Recruiting

  • The Ohio State University /ID# 267924

    Columbus, Ohio · Recruiting

  • Sooner Clinical Research /ID# 267881

    Oklahoma City, Oklahoma · Recruiting

  • Lehigh Center for Clinical Research /ID# 267908

    Allentown, Pennsylvania · Recruiting

  • Suburban Research Associates /ID# 267868

    West Chester, Pennsylvania · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.